



Protecting Ovaries from Chemotherapy Damage Using Proteasome Inhibitors

[View U.S. Patent No. 9,333,212 in PDF format.](#)

WARF: P130111US02

Inventors: Sana Salih, Elon Roti Roti

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for reducing chemotherapy damage to ovarian cells regardless of patient age or cancer type.

Overview

Primary ovary insufficiency (POI) caused by chemotherapy treatment is experienced by many cancer survivors, including up to 40 percent of reproductive-age breast cancer survivors and eight percent of childhood cancer survivors. The condition can lead to infertility and premature menopause, which increases a woman's risk for osteoporosis, mental health problems and cardiovascular disease.

Fertility preservation options—like the freezing of embryos and oocytes—are invasive, do not preserve endogenous estrogen and are not viable for young girls. Surgical removal and later re-implantation of ovarian tissue is available for children and women but is considered experimental and necessitates surgery to harvest and later transplant ovarian tissues.

There is a clear need to develop drug-based options aimed at preserving the long-term reproductive and endocrine health of female cancer survivors.

The Invention

UW–Madison researchers have developed a method to reduce ovarian damage in cancer patients by administering a proteasome inhibitor prior to chemotherapy.

The inhibitors work by binding to a cell's proteasome –the large complex of enzymes found in the cytoplasm that degrades and disposes old proteins. This binding action blocks chemotherapeutic agents from invading the cell nucleus.

To shield ovaries from chemotherapy toxicity, an effective dose of a proteasome inhibitor like bortezomib (Bort) or MG-132 is injected about an hour before treatment.

Applications

- Preserving ovarian health and fertility for cancer survivors without diminishing cancer care
- Preserving ovarian endocrine function and preventing chemotherapy-induced premature menopause in cancer survivors
- Preventing chemotherapy-induced delayed puberty in children diagnosed with cancer

Key Benefits

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

- Potential to reduce or prevent chemotherapy damage to human ovaries
- Preserves fertility
- Protects all types of ovarian cells

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

- Helps combat early menopause and risk to offspring
- Could work regardless of patient age or form of cancer
- Method is drug-based, hence non-invasive and cost-effective.

Publications

- Roti Roti E.C., Leisman S.K., Abbott D.H. and Salih S.M. 2012 Acute Doxorubicin Insult in the Mouse Ovary is Cell- and Follicle-Type Dependent. PLoS One.7(8):e42293

Tech Fields

- [Therapeutics & Vaccines : Oncology](#)
- [Therapeutics & Vaccines : Reproduction & infertility](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy](#).

OK



WARF | info@warf.org | 608.960.9850

Wisconsin Alumni Research Foundation